News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Avantium Technologies Provides Crystal16(TM) To All Research Sites Of Sanofi-Aventis (France) (SASY.PA)


9/5/2006 10:16:43 AM

AMSTERDAM, The Netherlands, September 5 /PRNewswire/ -- Avantium Technologies announced today an agreement with Sanofi-Aventis for the deployment of its proprietary Crystal16(TM) at all research & development centers of Sanofi-Aventis. Sanofi-Aventis has selected the Crystal16(TM) for the enhancement of its crystallization research capabilities, to increase the experimental throughput of its scientists and to be able to perform crystallization experiments on a smaller scale.

"We are pleased to provide our Crystal16(TM) platform to the global Sanofi-Aventis research organization", commented Guus Scheefhals, Chief Business Officer at Avantium, "this agreement validates Avantium's strategy to provide high-value added tools next to its services business".

The Crystal16(TM) is a novel and proprietary platform for performing parallel crystallization experiments in 1-ml reactors. The Crystal16(TM) can be used for a range of applications in pharmaceutical and chemical research, such as solubility measurements, improving the understanding of crystallization processes and the generation of crystals for product characterization. Users of the Crystal16(TM) are capable of running 16 experiments in parallel, using minimum quantities of precious starting materials while retrieving maximum knowledge about the crystallization process and solid-state of their product. More information can be found at www.crystal16.com.

About Avantium Technologies:

Avantium Technologies is a privately held, innovation-based research company located in Amsterdam, the Netherlands. Avantium provides high-throughput experimentation services and technologies to the chemicals and life science industries to enable companies to accelerate Research & Development. Avantium's proprietary technology platforms and skill sets reduce the time-to-market of new products and processes and improve the economics and success rate of research. Avantium collaborates with more than 40 pharmaceutical and chemical companies worldwide.

For more information, visit: www.avantium.com.

Source: Avantium Technologies B.V.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES